Which laboratory tests should be monitored before and during weekly methotrexate therapy for psoriasis, including baseline CBC, liver function tests, renal function, pregnancy test, hepatitis B/C and HIV screening, and serum PIIINP?

Laboratory Monitoring for Weekly Methotrexate in Psoriasis

For patients on weekly methotrexate therapy for psoriasis, perform baseline CBC, liver function tests (AST/ALT), renal function (creatinine/BUN), and hepatitis B/C serology, then monitor CBC and liver enzymes every 7-14 days for the first month, followed by every 3 months once stable. 1, 2

Baseline Laboratory Assessment

Before initiating methotrexate, obtain the following tests 1, 2, 3:

• Complete blood count (CBC) with differential and platelet count
• Liver function tests: AST, ALT, albumin
• Renal function: Creatinine, BUN, calculated creatinine clearance
• Hepatitis B and C serology
• Pregnancy test (for women of childbearing potential)
• Serum PIIINP (procollagen III N-terminal peptide) - specifically for psoriasis patients 2

Optional Baseline Tests (Risk-Dependent)

Consider these additional tests based on individual risk factors 4:

• HIV serology (in at-risk populations)
• HbA1c and fasting glucose (metabolic syndrome screening)
• Non-fasting lipid panel
• Chest X-ray (patients >40 years who smoke or have respiratory disease history) 2
• QuantiFERON-TB Gold test (high-risk populations)

Monitoring Schedule During Treatment

Initial Phase (First Month)

Monitor CBC, AST, ALT, and creatinine every 7-14 days during the first month of therapy 2, 3. This intensive early monitoring detects acute hematologic or hepatic toxicity when patients are most vulnerable to dose-related adverse effects.

Maintenance Phase (After First Month)

Once therapy is stabilized 1, 2:

• CBC: Every 3 months (can extend to every 3-6 months if consistently normal)
• Liver function tests (AST/ALT): Every 3 months
• Renal function: Every 3-6 months
• Serum PIIINP: Every 3 months (for psoriasis patients only) 2

The evidence strongly supports that monitoring every 3-6 months is adequate for stable patients, with recent data showing that extending monitoring intervals to 6 months does not increase detection delays for clinically significant abnormalities 5. In fact, overly frequent monitoring may lead to false-positive results and unnecessary treatment discontinuation 6.

Special Monitoring Considerations

Liver Toxicity Monitoring

The approach differs based on baseline risk 1:

Low-risk patients (no metabolic syndrome, minimal alcohol use):

• Standard LFT monitoring every 3-6 months
• PIIINP at baseline and every 3 months for psoriasis patients 2

High-risk patients (obesity, diabetes, fatty liver disease, alcohol use):

• Same monitoring frequency as low-risk patients
• Consider vibration-controlled transient elastography (FibroScan) at baseline
• Refer to GI/hepatology if PIIINP >8 mg/L on two occasions, three measurements >4.2 mg/L in 12 months, or >10 mg/L on one occasion 2

Critical caveat: Persistent LFT elevations warrant repeat testing in 2-4 weeks. If abnormalities persist, refer to gastroenterology rather than continuing methotrexate 1. The routine use of liver biopsy for monitoring is not recommended 2.

Response to Abnormal Results

For elevated transaminases: Repeat in 2-4 weeks. If persistently elevated, hold methotrexate and refer to gastroenterology 1, 3.

For cytopenias: Any significant drop in CBC parameters requires immediate dose reduction or discontinuation and repeat testing within days 3.

For renal dysfunction: Reduce dose if creatinine clearance falls below 60 mL/min; avoid methotrexate entirely if <20 mL/min or on dialysis 2, 3.

Common Pitfalls to Avoid

1. Over-monitoring leads to treatment discontinuation: Dermatology guidelines historically recommended more frequent monitoring than rheumatology, resulting in 44% higher costs and more false-positive results leading to premature drug discontinuation without improved safety 6, 7.

2. Ignoring metabolic syndrome: The primary driver of liver toxicity in psoriasis patients is underlying non-alcoholic fatty liver disease, not methotrexate itself 4, 8, 9. Screen for and manage obesity, diabetes, and hyperlipidemia aggressively.

3. Unnecessary test doses: Recent evidence shows test doses (≤15 mg with labs at 3-10 days) detect grade 2+ abnormalities in only 2.73% of patients and provide minimal clinical benefit 10. The 2020 AAD-NPF guidelines suggest test doses should only be considered in patients with impaired kidney function 1.

4. Forgetting pregnancy screening: Methotrexate is absolutely contraindicated in pregnancy. Women of childbearing potential require baseline pregnancy testing and reliable contraception throughout therapy 1, 3.

5. Missing infectious disease screening: Baseline hepatitis B/C serology is essential, as reactivation can occur. HIV testing should be considered in at-risk populations 1, 4.

Practical Algorithm Summary

Baseline → CBC, LFTs, creatinine, hepatitis B/C, pregnancy test (if applicable), PIIINP

Weeks 1-4 → CBC, AST/ALT, creatinine every 7-14 days

Months 2+ → CBC and LFTs every 3 months; creatinine every 3-6 months; PIIINP every 3 months (psoriasis only)

If abnormal → Repeat in 2-4 weeks; if persistent, hold drug and refer to specialist

This evidence-based approach balances safety with practicality, avoiding the over-monitoring that leads to unnecessary treatment discontinuation while maintaining adequate surveillance for genuine toxicity 1, 2, 6, 5.